Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19

Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases.

Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating that 56% of adults in the study who had newly positive levels of antibodies to SARS-CoV-2 in their blood during the Omicron surge were unaware of any recent COVID-19 infection. The findings suggest that low rates of Omicron variant infection awareness may be a key contributor to rapid transmission of the virus within communities.

Click here to read the full press release from Cedars-Sinai.

Click here to access the full JAMA Network Open paper, “Awareness of SARS-CoV-2 Omicron Variant Infection Among Adults With Recent COVID-19 Seropositivity”.

We look forward our continued collaboration, leveraging Sapient’s state-of-the art technologies and biocomputational approaches for biomarker discovery to facilitate Cedar-Sinai’s groundbreaking research into the patterns and predictors of immune and inflammatory responses.